Patent intelligence · US
US 6100252
Heterocyclic compounds and their use as angiotensin antagonists
Heterocyclic compounds and their use as angiotensin antagonists
Patent details — US 6100252
- Jurisdiction
- US
- Status
- expired
- Grant date
- Aug 8, 2000
- Expiration
- Aug 3, 2020
- Applicant
- Takeda Chemical Industries Ltd.
- Claims
- 21
- CPC classes
- A61K, A61K31/42, A61K31/435, A61P
Quick answer
US 6100252 (Heterocyclic compounds and their use as angiotensin antagonists) is held by Takeda Chemical Industries Ltd.. Status: expired. Granted Aug 8, 2000. Expires Aug 3, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Takeda Chemical Industries Ltd.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K31/42, A61K31/435, A61P, A61P25/28, A61P43/00
More from Takeda Chemical Industries Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12428403
N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists
granted -
US 12421188
Heterocyclic compound and use thereof
granted -
US 12419890
Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
granted -
US 12415866
Monoclonal antibody inhibitor of Factor XIIa
granted -
US 12415782
Heterocyclic compound and use thereof
granted -
US 12409210
CNS delivery of therapeutic agents
granted -
US 12404237
Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives
granted -
US 12403154
Administration of sting agonist and checkpoint inhibitors
granted
Frequently asked questions
What is US patent 6100252?
US 6100252 (Heterocyclic compounds and their use as angiotensin antagonists) is held by Takeda Chemical Industries Ltd.. Status: expired. Granted Aug 8, 2000. Expires Aug 3, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6100252?
Takeda Chemical Industries Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.
When does US 6100252 expire?
Our index shows an expiration date of Aug 3, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.